Macular degeneration: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Regeneron Pharmaceuticals· Source

• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Janssen Research & Development, LLC· Source

• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

  NCT04853251· Genentech, Inc.· Source

• Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

  NCT06018558· Ocugen· Source

• Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss

  NCT07216924· University of Minnesota· Source

• A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Hoffmann-La Roche· Source

• Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· AbbVie· Source

• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Apellis Pharmaceuticals, Inc.· Source

• A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

  NCT05230537· Novartis Pharmaceuticals· Source

• Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 24
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 23

See which targets of this disease your abstract mentions, and go to the people working on them.